Is this it now every RNS we get a deluge of negativity warning us not to trust Avacta?
Let's see what the poster tells us when it's released on the day. It's not going to be worse than what they told us in December. Which was actually very good.
I guess the hope is as big pharma executives wander around the poster hall they stop and ask if this work is funded for phase 2. Funny you should ask....
AVA6000 a tumour activated form of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in safety compared with standard doxorubicin, and early signs of clinical activity.